Gland Pharma has announced the appointment of Shyamakant Giri as its new Chief Executive Officer (CEO), effective January 15, 2025. This decision was approved by the company’s Board of Directors based on the recommendation of the Nomination and Remuneration Committee, signaling a strategic move to lead the company through its next phase of growth.
Giri is an accomplished business leader with over 25 years of experience across the pharmaceutical, healthcare, diagnostics, and medical device sectors. He has worked extensively in markets across Asia, Africa, MENA, and LATAM, holding senior leadership positions in both Indian and multinational organizations. Giri is recognized for his expertise in business development, operations, strategy, and his ability to scale new ventures and turnaround existing businesses.
Currently serving as President (India Business & Emerging Markets) at Amneal Pharmaceuticals, Giri has been instrumental in driving commercial growth in India and international markets. Prior to this, he was the CEO of Rivaara Labs and held multiple leadership roles over an 18-year tenure with Abbott India, AbbVie, and Abbott Diagnostics. Giri began his career with Wockhardt in 1999.
Giri holds a Master’s in Marketing Management from Jamnalal Bajaj Institute of Management Studies and a Master’s in Organic Chemistry from Mumbai University. He has also completed executive programs at INSEAD, Singapore, and the Indian Institute of Management, Ahmedabad.
Srinivas Sadu will continue to serve as Executive Chairman of Gland Pharma, providing strategic support to the company’s ongoing growth initiatives.
About Gland Pharma
Gland Pharma is a generic injectables manufacturer that specializes in sterile injectables, oncology, and ophthalmic products.
